Kalamazoo, Michigan, Oct. 29, 2019 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the third quarter of 2019:
Third Quarter Highlights
"We delivered another strong quarter of results, with organic sales growth of 8.6% and adjusted EPS growth of 13%," said Kevin A. Lobo, Chairman and Chief Executive Officer. "We expect this momentum to continue, which positions us well to deliver above the high end of our initial guidance range for both organic sales and adjusted EPS."
Sales Analysis
Consolidated net sales of $3.6 billion increased 10.6% in the quarter and 11.5% in constant currency. Organic net sales increased 8.6% in the quarter including 9.3% from increased unit volume partially offset by 0.7% from lower prices.
Orthopaedics net sales of $1.3 billion increased 7.8% in the quarter and 8.8% in constant currency. Organic net sales increased 8.8% in the quarter including 10.1% from increased unit volume partially offset by 1.3% from lower prices.
MedSurg net sales of $1.6 billion increased 9.2% in the quarter and 10.0% in constant currency. Organic net sales increased 8.8% in the quarter including 9.2% from increased unit volume partially offset by 0.4% from lower prices.
Neurotechnology and Spine net sales of $0.7 billion increased 19.4% in the quarter and 20.2% in constant currency. Organic net sales increased 7.6% in the quarter including 7.8% from increased unit volume partially offset by 0.2% from lower prices.
Earnings Analysis
Reported net earnings of $466 million decreased 21.0% in the quarter. Reported net earnings per diluted share of $1.23 decreased 20.6% in the quarter. Reported gross profit margin and reported operating income margin were 65.0% and 17.5% in the quarter. Adjusted gross profit margin(1) and adjusted operating income margin(1) were 65.7% and 25.4%, an improvement of 50 basis points in the quarter. Adjusted net earnings(1) of $725 million increased 12.8% in the quarter. Adjusted net earnings per diluted share(1) of $1.91 increased 13.0% in the quarter.
2019 Outlook
Based on our performance to date and anticipated strength in the remainder of the year, we now expect 2019 organic net sales growth to be toward the higher end of our previously guided range of 7.5% to 8.0% and expect adjusted net earnings per diluted share(2) to be in the range of $8.20 to $8.25. For the fourth quarter we expect adjusted net earnings per diluted share(2) to be in the range of $2.43 to $2.48. If foreign currency exchange rates hold near current levels, we expect net sales in the fourth quarter and full year will be negatively impacted by approximately 1.0%, and net earnings per diluted share will be negatively impacted by approximately $0.02 in the fourth quarter and $0.15 in the full year.
(1) A reconciliation of the non-GAAP financial measures: adjusted gross profit margin, adjusted operating income and adjusted operating income margin, adjusted net earnings and adjusted net earnings per diluted share, to the most directly comparable GAAP measures: gross profit margin, operating income and operating income margin, net earnings and net earnings per diluted share, and other important information accompanies this press release.
(2) We are unable to present a quantitative reconciliation of our expected net earnings per diluted share to expected adjusted net earnings per diluted share as we are unable to predict with reasonable certainty and without unreasonable effort the impact and timing of restructuring-related and other charges, acquisition-related expenses and fair value adjustments to inventory and the outcome of certain regulatory, legal and tax matters. The financial impact of these items is uncertain and is dependent on various factors, including timing, and could be material to our Consolidated Statements of Earnings.
Conference Call on Tuesday, October29, 2019
As previously announced, Stryker will host a conference call on Tuesday, October29, 2019 at 4:30 p.m., Eastern Time, to discuss the company's operating results for the quarter ended September30, 2019 and provide an operational update.
To participate in the conference call dial (877) 702-4565 (domestic) or (647) 689-5532 (international) and be prepared to provide conference ID number 6039299 to the operator.
A simultaneous webcast of the call will be accessible via the company's website at http://www.stryker.com. The call will be archived on the Investor Relations page of this site.
A recording of the call will also be available from 8:00 p.m., Eastern Time, on Tuesday, October29, 2019, until 11:59 p.m., Eastern Time, on Tuesday, November 5, 2019. To hear this recording, you may dial (800) 585-8367 (domestic) or (416) 621-4642 (international) and enter conference ID number 6039299.
Caution Concerning Forward-Looking Statements
This press release contains information that includes or is based on forward-looking statements within the meaning of the federal securities laws that are subject to various risks and uncertainties that could cause our actual results to differ materially from those expressed or implied in such statements. Such factors include, but are not limited to: weakening of economic conditions that could adversely affect the level of demand for our products; pricing pressures generally, including cost-containment measures that could adversely affect the price of or demand for our products; changes in foreign exchange markets; legislative and regulatory actions; unanticipated issues arising in connection with clinical studies and otherwise that affect U.S. Food and Drug Administration approval of new products; potential supply disruptions; changes in reimbursement levels from third-party payors; a significant increase in product liability claims; the ultimate total cost with respect to recall-related matters; the impact of investigative and legal proceedings and compliance risks; resolution of tax audits; the impact of the federal legislation to reform the United States healthcare system; costs to comply with medical device regulations; changes in financial markets; changes in the competitive environment; our ability to integrate acquisitions; and our ability to realize anticipated cost savings. Additional information concerning these and other factors is contained in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.
Stryker is one of the world's leading medical technology companies and,together with its customers, is driven to make healthcare better. The company offers innovative products and services inOrthopaedics, Medical and Surgical,and Neurotechnology and Spine that help improvepatient and hospital outcomes. More information is available atwww.stryker.com.
For investor inquiries please contact:
Katherine Owen, Vice President, Strategy & Investor Relations at 269-385-2600 or katherine.owen@stryker.com
For media inquiries please contact:
Yin Becker, Vice President, Communications, Public Affairs and Corporate Marketing at 269-385-2600 or yin.becker@stryker.com
nm - not meaningful
SUPPLEMENTAL INFORMATION - RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES
We supplement the reporting of our financial information determined under accounting principles generally accepted in the United States (GAAP) with certain non-GAAP financial measures, including: percentage sales growth; percentage sales growth in constant currency; percentage organic sales growth; adjusted gross profit; adjusted selling, general and administrative expenses; adjusted research, development and engineering expenses; adjusted operating income; adjusted effective income tax rate; adjusted net earnings; and adjusted net earnings per diluted share (Diluted EPS). We believe that these non-GAAP financial measures provide meaningful information to assist investors and shareholders in understanding our financial results and assessing our prospects for future performance. Management believes percentage sales growth in constant currency and the other adjusted measures described above are important indicators of our operations because they exclude items that may not be indicative of or are unrelated to our core operating results and provide a baseline for analyzing trends in our underlying businesses. Management uses these non-GAAP financial measures for reviewing the operating results of reportable business segments and analyzing potential future business trends in connection with our budget process and bases certain management incentive compensation on these non-GAAP financial measures.
To measure percentage sales growth in constant currency, we remove the impact of changes in foreign currency exchange rates that affect the comparability and trend of sales. Percentage sales growth in constant currency is calculated by translating current and prior year results at the same foreign currency exchange rate. To measure percentage organic sales growth, we remove the impact of changes in foreign currency exchange rates and acquisitions, which affect the comparability and trend of sales. Percentage organic sales growth is calculated by translating current year results at prior year average foreign currency exchange rates excluding the impact of acquisitions. To measure earnings performance on a consistent and comparable basis, we exclude certain items that affect the comparability of operating results and the trend of earnings.
Because non-GAAP financial measures are not standardized, it may not be possible to compare these financial measures with other companies' non-GAAP financial measures having the same or similar names. These adjusted financial measures should not be considered in isolation or as a substitute for reported sales growth, gross profit, selling, general and administrative expenses, research, development and engineering expenses, operating income, effective income tax rate, net earnings and net earnings per diluted share, the most directly comparable GAAP financial measures. These non-GAAP financial measures are an additional way of viewing aspects of our operations that, when viewed with our GAAP results and the reconciliations to corresponding GAAP financial measures below, provide a more complete understanding of our business. We strongly encourage investors and shareholders to review our financial statements and publicly-filed reports in their entirety and not to rely on any single financial measure.
The following reconciles the non-GAAP financial measures discussed above with the most directly comparable GAAP financial measures. The weighted-average diluted shares outstanding used in the calculation of non-GAAP earnings per share are the same as those used in the calculation of reported earnings per share for the respective period.
Excerpt from:
Stryker reports third quarter 2019 operating results - BioSpace
- Systems-Based Neurotechnology for Emerging Therapies (SUBNETS) - December 8th, 2016 [December 8th, 2016]
- Backing British innovation: Royal Academy of Engineering launches ... - Elite Business Magazine - February 13th, 2017 [February 13th, 2017]
- Global Fingerprint Biometrics in the VAR Market 2016 Fulcrum Biometrics, Neurotechnology, 360 Biometrics ... - Albanian Times - February 16th, 2017 [February 16th, 2017]
- Israel and Indiana: Why You're Getting an Invitation to the Holy Land ... - 93.1 WIBC Indianapolis - February 22nd, 2017 [February 22nd, 2017]
- 5th Annual Big Idea Competition Nets Three Winners Colorado ... - Colorado College News - February 23rd, 2017 [February 23rd, 2017]
- 3Q: US Patent Office's Ruling on CRISPR - Bioscience Technology - February 24th, 2017 [February 24th, 2017]
- 7 reasons you must attend WIRED Health 2017 - Wired.co.uk - February 24th, 2017 [February 24th, 2017]
- Edward Boyden - Big Think - February 25th, 2017 [February 25th, 2017]
- What Health Care Can Learn from Wal-Mart - Wall Street Journal (subscription) (blog) - March 4th, 2017 [March 4th, 2017]
- A report released today by RBC Capital Markets about Stryker Corporation (NYSE:SYK) ups the target price to $135.00 - Breaking Finance News - March 4th, 2017 [March 4th, 2017]
- Paralysis patients achieve fastest typing yet with new brain-computer interface - The Brown Daily Herald - March 7th, 2017 [March 7th, 2017]
- How 'brain wearables' can address 21st century needs - IoT Tech News - March 7th, 2017 [March 7th, 2017]
- Stryker's AVAflex Vertebral Balloon System Receives FDA 510(k ... - OrthoSpineNews - March 8th, 2017 [March 8th, 2017]
- Stryker's Spine Division To Feature Novel 3D-Printed Spinal Implants at AAOS Conference - OrthoSpineNews - March 9th, 2017 [March 9th, 2017]
- Stryker's Spine division to exhibit key technologies at AAOS 2017 - Yahoo Finance - March 9th, 2017 [March 9th, 2017]
- Stryker Corporation named one of Fortune Magazine's 100 Best Companies to Work For for seventh consecutive year - Yahoo Finance - March 9th, 2017 [March 9th, 2017]
- How to ensure future brain technologies will help and not harm society - USAPP American Politics and Policy (blog) - March 10th, 2017 [March 10th, 2017]
- Preview: MedX Future of Healthcare conference - The Mancunion - March 11th, 2017 [March 11th, 2017]
- Stryker's Spine division to exhibit key technologies at AAOS 2017 - OrthoSpineNews - March 11th, 2017 [March 11th, 2017]
- Elon Musk Wants to Merge Man and MachineHere's What He'll ... - Observer - April 8th, 2017 [April 8th, 2017]
- Synchron Inc. Secures $10 Million in Series A Financing Round - PR Newswire (press release) - April 8th, 2017 [April 8th, 2017]
- How Neurotechnology Is Helping The San Francisco Giants Train Better - PSFK (subscription) - April 8th, 2017 [April 8th, 2017]
- Positive Media Coverage Very Likely to Affect Stryker (SYK) Share Price - Chaffey Breeze - June 6th, 2017 [June 6th, 2017]
- Shoosmiths advises PD Neurotechnology on 1.34m investment - Scottish Legal News - June 6th, 2017 [June 6th, 2017]
- Shoosmiths advises PD Neurotechnology on 1.34m (EUR) investment - Shoosmiths legal updates (press release) - June 7th, 2017 [June 7th, 2017]
- Comparing Accuray (ARAY) & Stryker (SYK) - The Cerbat Gem - June 9th, 2017 [June 9th, 2017]
- Welch Capital Partners Increased By $3.59 Million Its Eqt (EQT) Position, Stryker (SYK) Sellers Decreased By 3.59 ... - UtahHerald.com - June 10th, 2017 [June 10th, 2017]
- Head to Head Analysis: Accuray (ARAY) and Stryker Corporation (SYK) - Sports Perspectives - June 13th, 2017 [June 13th, 2017]
- Neurotechnology Announces MegaMatcher Accelerator Extreme ... - findBIOMETRICS - June 13th, 2017 [June 13th, 2017]
- Comparing Stryker Corporation (SYK) & Accuray (ARAY) - Markets Daily - June 14th, 2017 [June 14th, 2017]
- Neurotechnology Releases MegaMatcher Accelerator Extreme, the Fastest Biometric Engine in the World - PR Newswire (press release) - June 14th, 2017 [June 14th, 2017]
- Neurotech panel shares successes from first year - Cornell Chronicle - June 14th, 2017 [June 14th, 2017]
- Neurotechnology Researchers Win Kaggle Competition with Deep Neural Network Solution for The Nature ... - PR Newswire (press release) - June 14th, 2017 [June 14th, 2017]
- Neurotechnology Wins Fisheries-Focused Computer Vision Competition - findBIOMETRICS - June 14th, 2017 [June 14th, 2017]
- Helping or Hacking? Engineers, Ethicists Must Work Together on Brain-Computer Interface Technology - Government Technology - June 16th, 2017 [June 16th, 2017]
- Accuray (ARAY) versus Stryker Corporation (SYK) Head-To-Head Review - The Cerbat Gem - June 17th, 2017 [June 17th, 2017]
- The Funded: Justin Kan's latest startup gets backing from more than 100 investors - Silicon Valley Business Journal - June 17th, 2017 [June 17th, 2017]
- New SentiVeillance Server from Neurotechnology Adds Face Recognition and Analytics to Video Management Systems - PR Newswire (press release) - June 20th, 2017 [June 20th, 2017]
- Neurotechnology Announces SentiVeillance Server Facial Recognition Solution - findBIOMETRICS - June 20th, 2017 [June 20th, 2017]
- SentiVeillance Server - Face Recognition and Analytics to Video Management Systems - Officer.com (press release) (registration) (blog) - June 21st, 2017 [June 21st, 2017]
- Neurotechnology Announces MegaMatcher 10 - findBIOMETRICS - June 21st, 2017 [June 21st, 2017]
- Neurotechnology adds face recognition, tracking to video surveillance systems; researchers win competition - Biometric Update - June 22nd, 2017 [June 22nd, 2017]
- Neurotechnology makes a number of updates to the MegaMatcher product line - Biometric Update - June 23rd, 2017 [June 23rd, 2017]
- Neurotechnology Develops 3D Printing Method with Non-Contact Ultrasonic Manipulation Technology - 3DPrint.com - June 26th, 2017 [June 26th, 2017]
- Mind-blowing ultrasonic 'printer' uses lasers and high-frequency sound to assemble electronics - Digital Trends - June 29th, 2017 [June 29th, 2017]
- HIRREM Neurotechnology Better Than Placebo for Insomnia - Sleep Review - July 10th, 2017 [July 10th, 2017]
- DARPA invests further in neurotechnology - SD Times - SDTimes.com - July 14th, 2017 [July 14th, 2017]
- Infinitely Flexible 3D Printing with Ultrasonic Manipulation? - ENGINEERING.com - July 15th, 2017 [July 15th, 2017]
- Insider Activity Stryker Corporation (NYSE:SYK) - Highlight Press - July 16th, 2017 [July 16th, 2017]
- Comparing Uroplasty (UPI) and Stryker Corporation (NYSE:SYK) - The Cerbat Gem - July 17th, 2017 [July 17th, 2017]
- Biomimetic Underwater Robot Program - July 17th, 2017 [July 17th, 2017]
- Preserving the Right to Cognitive Liberty - Scientific American - July 18th, 2017 [July 18th, 2017]
- BRAIN center gathers to ponder future, direction - Arizona State University - July 20th, 2017 [July 20th, 2017]
- Stryker Expands Its Interventional Spine Segment - Market Realist - July 22nd, 2017 [July 22nd, 2017]
- Trivascular Technologies (TRIV) & Stryker Corporation (SYK) Critical Review - Stock Observer - July 26th, 2017 [July 26th, 2017]
- Arshya Vahabzadeh: Innovating at the Intersection of Brain ... - HuffPost - July 27th, 2017 [July 27th, 2017]
- fMRI and EEG May Be Able to Reveal Consciousness in Comatose Patients - Physical Therapy Products - July 29th, 2017 [July 29th, 2017]
- Stryker reports 6.1% Q2 growth, installs 26 Mako systems: 7 things to know - Becker's Orthopedic & Spine - July 29th, 2017 [July 29th, 2017]
- Tufts Hosts Engineering Conference - Tufts Now - July 29th, 2017 [July 29th, 2017]
- Stryker Corporation (NYSE:SYK) and Uroplasty (UPI) Financial Survey - Stock Observer - July 29th, 2017 [July 29th, 2017]
- Elon Musk speaks of being 'bipolar' on Twitter - Mashable - July 31st, 2017 [July 31st, 2017]
- Team Neurotechnology Innovations Translator - July 31st, 2017 [July 31st, 2017]
- Elon Musk opens up about the highs and lows of his life on Twitter - Firstpost - August 1st, 2017 [August 1st, 2017]
- Train your brain at Ky learning centre - Shepparton News - August 2nd, 2017 [August 2nd, 2017]
- Stryker Exceeded Analysts' Sales Estimates in 2Q17 - Market Realist - August 2nd, 2017 [August 2nd, 2017]
- $2.6 million to build versatile genetic toolkit for studying animal ... - Washington University in St. Louis Newsroom - August 3rd, 2017 [August 3rd, 2017]
- National Science Foundation $9M grant will fund neurotech research hub at Cornell - The Ithaca Voice - August 3rd, 2017 [August 3rd, 2017]
- NSF awards Cornell $9M grant for neurotech research hub - The Central New York Business Journal - August 4th, 2017 [August 4th, 2017]
- NSF issues awards to advance a national research infrastructure for neuroscience - National Science Foundation (press release) - August 4th, 2017 [August 4th, 2017]
- $9M Grant Will Create Neurotech Research Hub - Lansing Star - August 4th, 2017 [August 4th, 2017]
- NSF backs photonics-enabled neuroscience networks - Optics.org - August 9th, 2017 [August 9th, 2017]
- Washington University awarded $2.6 million for neurotechnology research - St. Louis Business Journal - August 9th, 2017 [August 9th, 2017]
- fMRI, EEG may detect consciousness in TBI patients - Medical Physics Web (subscription) - August 10th, 2017 [August 10th, 2017]
- Financial Analysis: Stryker Corporation (NYSE:SYK) vs. Uroplasty (UPI) - The Cerbat Gem - August 12th, 2017 [August 12th, 2017]
- In the Future, Humans Will Use Brain to Brain Communication and Download Their Memories If Elon Musk Has His Way - Newsweek - August 13th, 2017 [August 13th, 2017]
- How Elon Musk Plans to Turn Humans Into Robots - Yahoo News - August 14th, 2017 [August 14th, 2017]
- Critical Comparison: Stryker Corporation (SYK) versus Glaukos Corporation (GKOS) - TrueBlueTribune - August 21st, 2017 [August 21st, 2017]
- Early career scientists named Mong Fellows in Cornell Neurotech - Cornell Chronicle - August 21st, 2017 [August 21st, 2017]
- Could this back-pain device end need for opioids? - The Columbus Dispatch - August 21st, 2017 [August 21st, 2017]
- New technologies to diagnose and treat neurological diseases - Medical Xpress - August 22nd, 2017 [August 22nd, 2017]